Common fragile sites are preferential targets for HPV16 integrations in cervical tumors

被引:198
|
作者
Thorland, EC
Myers, SL
Gostout, BS
Smith, DI
机构
[1] Mayo Clin & Mayo Fdn, Dept Expt Pathol, Rochester, MN 55905 USA
[2] Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA
[3] Mayo Clin & Mayo Fdn, Dept Tumor Biol, Rochester, MN 55905 USA
[4] Mayo Clin & Mayo Fdn, Dept Obstet & Gynecol, Rochester, MN 55905 USA
关键词
common fragile sites; cervical cancer; human papillomavirus; viral integration; RS-PCR;
D O I
10.1038/sj.onc.1206170
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The development of cervical cancer is highly associated with human papillomavirus (HPV) infection. HPV integration into the genome of infected cervical cells is temporally associated with the acquisition of the malignant phenotype. A relationship between the sites of HPV integration in cervical cancer and the position of the common fragile sites (CFSs) has been observed at both the cytogenetic and molecular levels. To further explore this relationship at the molecular level, we used RS-PCR to rapidly isolate cellular sequences flanking the sites of HPV16 integration in 26 primary cervical tumors. Human bacterial artificial chromosome clones were isolated based on these flanking sequences and used as probes for fluorescence in situ hybridization on aphidicolin-stimulated metaphases. Our data demonstrate that 11/23 HPV16 integrations in cervical tumors occurred within CFSs (P < 0.001). In addition, we show that deletions and complex rearrangements frequently occur in the cellular sequences targeted by the integrations and that integrations cluster in FRA13C (13q22), FRA3B (3p14.2), and FRA17B (17q23). Finally, our data suggest that cellular genes, such as Notch 1, are disrupted by the HPV16 integrations, which may contribute to the malignant phenotype.
引用
收藏
页码:1225 / 1237
页数:13
相关论文
共 50 条
  • [1] Common fragile sites are preferential targets for HPV16 integrations in cervical tumors
    Erik C Thorland
    Shannon L Myers
    Bobbie S Gostout
    David I Smith
    [J]. Oncogene, 2003, 22 : 1225 - 1237
  • [2] HPV16 integrations in cervical tumors preferentially occur within the common fragile sites and cluster at specific sites.
    Thorland, EC
    Myers, SL
    Gostout, BS
    Smith, DI
    [J]. AMERICAN JOURNAL OF HUMAN GENETICS, 2000, 67 (04) : 79 - 79
  • [3] HPV16 preferentially integrates into the common fragile sites in cervical cancer.
    Thorland, EC
    Myers, S
    Persing, D
    Smith, DI
    [J]. AMERICAN JOURNAL OF HUMAN GENETICS, 1999, 65 (04) : A11 - A11
  • [4] Human papillomavirus type 16 integrations in cervical tumors frequently occur in common fragile sites
    Thorland, EC
    Myers, SL
    Persing, DH
    Sarkar, G
    McGovern, RM
    Gostout, BS
    Smith, DI
    [J]. CANCER RESEARCH, 2000, 60 (21) : 5916 - 5921
  • [5] Fragile sites are preferential targets for integrations of MLV vectors in gene therapy
    Bester, A. C.
    Schwartz, M.
    Schmidt, M.
    Garrigue, A.
    Hacein-Bey-Abina, S.
    Cavazzana-Calvo, M.
    Ben-Porat, N.
    Von Kalle, C.
    Fischer, A.
    Kerem, B.
    [J]. GENE THERAPY, 2006, 13 (13) : 1057 - 1059
  • [6] Fragile sites are preferential targets for integrations of MLV vectors in gene therapy
    A C Bester
    M Schwartz
    M Schmidt
    A Garrigue
    S Hacein-Bey-Abina
    M Cavazzana-Calvo
    N Ben-Porat
    C Von Kalle
    A Fischer
    B Kerem
    [J]. Gene Therapy, 2006, 13 : 1057 - 1059
  • [7] Erratum: Fragile sites are preferential targets for integrations of MLV vectors in gene therapy
    A C Bester
    M Schwartz
    M Schmidt
    A Garrigue
    S Hacein-Bey-Abina
    M Cavazzana-Calvo
    N Ben-Porat
    C Von Kalle
    A Fischer
    B Kerem
    [J]. Gene Therapy, 2007, 14 : 282 - 282
  • [8] Are common fragile sites preferential targets for the integration of mitochondrial DNA during evolution?
    Mishmar, D
    Kilger, C
    Rahat, A
    Paabo, S
    Kerem, B
    [J]. AMERICAN JOURNAL OF HUMAN GENETICS, 1999, 65 (04) : A414 - A414
  • [9] Redetection of Cervical Human Papillomavirus Type 16 (HPV16) in Women With a History of HPV16
    Moscicki, Anna-Barbara
    Ma, Yifei
    Farhat, Sepideh
    Darragh, Teresa M.
    Pawlita, Michael
    Galloway, Denise A.
    Shiboski, Stephen
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2013, 208 (03): : 403 - 412
  • [10] Fragile sites are preferential targets for integrations of MLV vectors in gene therapy (vol 13, pg 1057, 2006)
    Bester, A. C.
    Schwartz, M.
    Schmidt, M.
    Garrigue, A.
    Hacein-Bey-Abina, S.
    Cavazzana-Calvo, M.
    Ben-Porat, N.
    Von Kalle, C.
    Fischer, A.
    Kerem, B.
    [J]. GENE THERAPY, 2007, 14 (03) : 282 - 282